Floatz logo

Ponatinib

Accelerated Phase Chronic Myeloid Leukemia

Incyte Biosciences International SàrlSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Accelerated Phase Chronic Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
University of Illinois at Chicago
Phase 2BBB
Cyclophosphamide
University of Illinois at Chicago
Phase 2BBB
CYCLOSPORIN A
University of Michigan Rogel Cancer Center
Phase 2BBB
METHOTREXATE
University of Michigan Rogel Cancer Center
Phase 2BB
TACROLIMUS
University of Michigan Rogel Cancer Center
Phase 2BB

View all 46 →

Same molecule, other indications

Ponatinib is also rated in:

chronic myeloid leukemiaDormant
BB
Indicative ·
66 / 100
View asset →
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
65 / 100
View asset →
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →